Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Exp Suppl ; 107: 45-71, 2016.
Article in English | MEDLINE | ID: mdl-27812976

ABSTRACT

In eukaryotic cells, AMP-activated protein kinase (AMPK) generally promotes catabolic pathways that produce ATP and at the same time inhibits anabolic pathways involved in different processes that consume ATP. As an energy sensor, AMPK is involved in the main cellular functions implicated in cell fate, such as cell growth and autophagy.Recently, AMPK has been connected with apoptosis regulation, although the molecular mechanism by which AMPK induces and/or inhibits cell death is not clear.This chapter reviews the essential role of AMPK in signaling pathways that respond to cellular stress and damage, highlighting the complex and reciprocal regulation between AMPK and their targets and effectors. The therapeutic implications of the role of AMPK in different pathologies such as diabetes, cancer, or mitochondrial dysfunctions are still controversial, and it is necessary to further investigate the molecular mechanisms underlying AMPK activation.


Subject(s)
AMP-Activated Protein Kinases/genetics , Apoptosis/genetics , Autophagy/genetics , Energy Metabolism/genetics , Eukaryotic Cells/enzymology , Gene Expression Regulation , AMP-Activated Protein Kinases/metabolism , Cell Cycle Checkpoints/genetics , Cell Proliferation , Eukaryotic Cells/cytology , Fatty Acids/metabolism , Glucose/metabolism , Humans , Lipogenesis/genetics , MAP Kinase Kinase 4/genetics , MAP Kinase Kinase 4/metabolism , Mechanistic Target of Rapamycin Complex 1 , Multiprotein Complexes/genetics , Multiprotein Complexes/metabolism , Protein Subunits/genetics , Protein Subunits/metabolism , Signal Transduction , TOR Serine-Threonine Kinases/genetics , TOR Serine-Threonine Kinases/metabolism , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Unfolded Protein Response/genetics
2.
Expert Opin Ther Targets ; 20(4): 487-500, 2016.
Article in English | MEDLINE | ID: mdl-26523761

ABSTRACT

INTRODUCTION: Mitochondrial diseases are a group of rare genetic diseases with complex and heterogeneous origins which manifest a great variety of phenotypes. Disruption of the oxidative phosphorylation system is the main cause of pathogenicity in mitochondrial diseases since it causes accumulation of reactive oxygen species (ROS) and ATP depletion. AREAS COVERED: Current evidences support the main protective role of autophagy and mitophagy in mitochondrial diseases and other diseases associated with mitochondrial dysfunction. EXPERT OPINION: The use of autophagy and/or mitophagy inducers may allow a novel strategy for improving mitochondrial function for both mitochondrial diseases and other diseases with altered mitochondrial metabolism. However, a deeper investigation of the molecular mechanisms behind mitophagy and mitochondrial biogenesis is needed in order to safely modulate these processes. In the coming years, we will also see an increase in awareness of mitochondrial dynamics modulation that will allow the therapeutic use of new drugs for improving mitochondrial function in a great variety of mitochondrial disorders.


Subject(s)
Mitochondria/drug effects , Mitochondrial Diseases/drug therapy , Molecular Targeted Therapy , Adenosine Triphosphate/metabolism , Animals , Autophagy/drug effects , Drug Design , Humans , Mitochondria/metabolism , Mitochondria/pathology , Mitochondrial Diseases/physiopathology , Mitophagy/drug effects , Reactive Oxygen Species/metabolism
3.
Cytoskeleton (Hoboken) ; 72(9): 435-46, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26382917

ABSTRACT

Apoptosis is a genetically programmed energy-dependent process of cell demise, characterized by specific morphological and biochemical events in which the activation of caspases has an essential role. During apoptosis the cytoskeleton participates actively in characteristic morphological rearrangements of the dying cell. This reorganisation has been assigned mainly to actinomyosin ring contraction, while microtubule and intermediate filaments are depolymerized at early stages of apoptosis. However, recent reports have showed that microtubules are reformed during the execution phase of apoptosis organizing an apoptotic microtubule network (AMN). AMN is organized behind plasma membrane, forming a cortical structure. Apoptotic microtubules repolymerization takes place in many cell types and under different apoptotic inducers. It has been hypothesized that AMN is critical for maintaining plasma membrane integrity and cell morphology during the execution phase of apoptosis. AMN disorganization leads apoptotic cells to secondary necrosis and the release of potential toxic molecules which can damage neighbor cells and promotes inflammation. Therefore, AMN formation during physiological apoptosis or in pathological apoptosis induced by anti-cancer treatments is essential for tissue homeostasis and the prevention of additional cell damage and inflammation.


Subject(s)
Apoptosis , Microtubules/physiology , Actomyosin/chemistry , Adenosine Triphosphate/chemistry , Caspases/metabolism , Cell Line, Tumor , Cell Membrane/physiology , Cell Membrane Permeability , Cytoskeleton/physiology , Homeostasis , Humans , Inflammation , Intermediate Filaments/chemistry , Macrophages/cytology , Polymers/chemistry
4.
Sci Rep ; 5: 10903, 2015 Jun 05.
Article in English | MEDLINE | ID: mdl-26045184

ABSTRACT

Gaucher disease (GD) is caused by mutations in the GBA1 gene, which encodes lysosomal ß-glucocerebrosidase. Homozygosity for the L444P mutation in GBA1 is associated with high risk of neurological manifestations which are not improved by enzyme replacement therapy. Alternatively, pharmacological chaperones (PCs) capable of restoring the correct folding and trafficking of the mutant enzyme represent promising alternative therapies.Here, we report on how the L444P mutation affects mitochondrial function in primary fibroblast derived from GD patients. Mitochondrial dysfunction was associated with reduced mitochondrial membrane potential, increased reactive oxygen species (ROS), mitophagy activation and impaired autophagic flux.Both abnormalities, mitochondrial dysfunction and deficient ß-glucocerebrosidase activity, were partially restored by supplementation with coenzyme Q10 (CoQ) or a L-idonojirimycin derivative, N-[N'-(4-adamantan-1-ylcarboxamidobutyl)thiocarbamoyl]-1,6-anhydro-L-idonojirimycin (NAdBT-AIJ), and more markedly by the combination of both treatments. These data suggest that targeting both mitochondria function by CoQ and protein misfolding by PCs can be promising therapies in neurological forms of GD.


Subject(s)
Enzyme Inhibitors/pharmacology , Gaucher Disease/metabolism , Glucosylceramidase/metabolism , Mitochondria/drug effects , Mitochondria/metabolism , Ubiquinone/analogs & derivatives , Autophagy/drug effects , Autophagy/genetics , Biomarkers , Enzyme Activation , Fibroblasts/drug effects , Fibroblasts/metabolism , Gaucher Disease/drug therapy , Gaucher Disease/genetics , Gene Expression , Glucosylceramidase/genetics , Humans , Mutation , Phagosomes/metabolism , Reactive Oxygen Species/metabolism , Ubiquinone/pharmacology
5.
Redox Biol ; 5: 416, 2015 08.
Article in English | MEDLINE | ID: mdl-28162276

ABSTRACT

Apoptosis is characterized by degradation of cell components but plasma membrane remains intact. Apoptotic microtubule network (AMN) is organized during apoptosis forming a cortical structure beneath plasma membrane that maintains plasma membrane integrity. Apoptotic cells are also characterized by high reactive oxygen species (ROS) production that can be potentially harmful for the cell. The aim of this study was to develop a method that allows stabilizing apoptotic cells for diagnostic and therapeutic applications. We were able by using a cocktail composed of taxol (a microtubule stabilizer), Zn2+ (a caspase inhibitor) and coenzyme Q10 (a lipid antioxidant) to stabilize H460 apoptotic cells in cell cultures for at least 72hours preventing secondary necrosis. Stabilized apoptotic cells maintain many apoptotic cells characteristics such as the presence of apoptotic microtubules, plasma membrane integrity, low intracellular calcium levels, plasma membrane potential, PS externalization and ability of being phagocytosed. Stabilized apoptotic cells can be considered as dying cells in which the cellular cortex and plasma membrane are maintained intact or alive. In a metaphorical sense, we can consider them as "living dead" or "zombie cells". Stabilization of apoptotic cells can be used for reliable detection and quantification of apoptosis in cultured cells and may allow a safer administration of apoptotic cells in clinical applications. Furthermore, it opens new avenues in the functional reconstruction of apoptotic cells for longer preservation.


Subject(s)
Apoptosis , Cell Membrane/metabolism , Membrane Potentials , Microtubules/metabolism , Animals , Cell Line , Cell Membrane/genetics , Humans , Microtubules/genetics
6.
Mol Syndromol ; 5(3-4): 187-97, 2014 Jul.
Article in English | MEDLINE | ID: mdl-25126052

ABSTRACT

For a number of years, coenzyme Q10 (CoQ10) was known for its key role in mitochondrial bioenergetics; later studies demonstrated its presence in other subcellular fractions and in blood plasma, and extensively investigated its antioxidant role. These 2 functions constitute the basis for supporting the clinical use of CoQ10. Also, at the inner mitochondrial membrane level, CoQ10 is recognized as an obligatory cofactor for the function of uncoupling proteins and a modulator of the mitochondrial transition pore. Furthermore, recent data indicate that CoQ10 affects the expression of genes involved in human cell signaling, metabolism and transport, and some of the effects of CoQ10 supplementation may be due to this property. CoQ10 deficiencies are due to autosomal recessive mutations, mitochondrial diseases, aging-related oxidative stress and carcinogenesis processes, and also statin treatment. Many neurodegenerative disorders, diabetes, cancer, and muscular and cardiovascular diseases have been associated with low CoQ10 levels as well as different ataxias and encephalomyopathies. CoQ10 treatment does not cause serious adverse effects in humans and new formulations have been developed that increase CoQ10 absorption and tissue distribution. Oral administration of CoQ10 is a frequent antioxidant strategy in many diseases that may provide a significant symptomatic benefit.

SELECTION OF CITATIONS
SEARCH DETAIL
...